Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611, Luxembourg
MIGARD 2.5 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Round biconvex white film-coated tablet, debossed with “m” on one side and “2.5” on the other. |
Each film-coated tablet contains 2.5 mg of frovatriptan (as succinate monohydrate).
Excipient(s) with known effects: approximately 100 mg of lactose per tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Frovatriptan |
Frovatriptan is a selective agonist for 5-HT receptors. Frovatriptan is believed to act selectively on extracerebral, intracranial arteries to inhibit the excessive dilatation of these vessels in migraine. |
| List of Excipients |
|---|
|
Tablet core: Lactose, anhydrous Tablet Coat: Opadry white: Hypromellose (E464) |
PVC/PE/PVDC/Aluminium blister packs with 1, 2, 3, 4, 6 and 12 tablets.
Not all pack sizes may be marketed.
Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611, Luxembourg
PL 16239/0017
Date of first authorisation: 7th October 2002
Date of latest renewal: 13th February 2008
| Drug | Countries | |
|---|---|---|
| MIGARD | Estonia, Finland, Lithuania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
